The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women: A Multicenter, Double-Blind, Placebo-Controlled Trial
Abstract
Objective: To evaluate the efficacy and safety of oral famciclovir in the suppression of genital herpes. Methods: In this randomized, double-blind, placebo-controlled trial that was performed at 11 university and 9 private ambulatory care referral centers, 375 women who were 18 years of age or older and had a history of 6 or more episodes of genital herpes during 12 of the last 24 months in the absence of suppressive therapy were treated for 4 months with oral famciclovir, 125 mg once daily or twice daily, 250 mg once daily or twice daily, 500 mg once daily, or placebo. The primary outcome measures included the time to first clinically and virologically confirmed recurrences, and safety as measured by clinical laboratory tests and adverse experiences. Results: The median time to first recurrence was 82 days in the placebo group, 114 days in those receiving famciclovir, 125 mg once daily, and more than 120 days in the other treatment groups. When compared with placebo recipients, the time to the first clinical recurrence was significantly prolonged in subjects who received famciclovir, 125 mg twice daily (hazard ratio, 1.8; 95% confidence interval, 1.0-3.0;P=.03), and in those who received famciclovir, 250 mg twice daily (hazard ratio, 3.6; 95% confidence interval, 1.9-6.9;P<.001). Treatment was well tolerated, and there was no evidence of emergence of resistance during or after suppressive famciclovir therapy. Conclusions: Oral famciclovir, 250 mg, given twice daily for 4 months is an effective, well-tolerated treatment for the suppression of genital herpes in women with frequent recurrences, but single daily doses produced less complete suppression of genital herpes. Arch Intern Med. 1997;157:343-349
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Suppressive therapy reduces frequency of genital herpes recurrences by 70%–80% among patients who have frequent recurrences (469–472).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [470]
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Genital Herpes Simplex Virus Infections: Clinical Manifestations, Course, and Complications
Corey, L., ADAMS, H. G., BROWN, Z. A., & HOLMES, K. K. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-958 · Cited by 928
Virologic Characteristics of Subclinical and Symptomatic Genital Herpes Infections
Wald, A., Zeh, J. E., Selke, S., Ashley, R. L., & Corey, L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509213331205 · Cited by 504
Tyring, S. K., Barbarash, R. A., Nahlik, J. E., Cunningham, A. L., Marley, J. E., Heng, M. C. Y., Jones, T., Rea, T., Boon, R. J., Saltzman, R. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00002 · Cited by 488
Risk Factors for the Sexual Transmission of Genital Herpes
MERTZ, G. J., Benedetti, J., Ashley, R. L., Selke, S., & Corey, L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-3-197 · Cited by 473
Self-citationPharmacokinetics of acyclovir after intravenous and oral administration
de Miranda, P., & Blum, M. R. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.suppl_b.29 · Cited by 382
Douglas, J. M., Critchlow, C. W., Benedetti, J., MERTZ, G. J., Connor, J. D., Hintz, M. A., Fahnlander, A., Remington, M. L., Winter, C., & Corey, L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198406143102402 · Cited by 336
Self-citationSuppression of Frequently Recurring Genital Herpes
Straus, S. E., Tariff, H. E., Seidlin, M., Bachrach, S., Lininger, L. L., DiGiovanna, J. J., Western, K. A., Smith, H. A., Lehrman, S. N., Creagh-Kirk, T., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198406143102401 · Cited by 319
Suppression of Subclinical Shedding of Herpes Simplex Virus Type 2 with Acyclovir
Wald, A., Zeh, J., Barnum, G., Davis, L. G., & Corey, L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_1-199601010-00002 · Cited by 261
MERTS, G. J., Schmidt, O. W., Jourden, J., Guinan, M. E., Remington, M. L., FAHBLANDER, A., Winter, C., Holmes, K. K., & Corey, L. (1985) · Sexually Transmitted Diseases · doi:10.1097/00007435-198501000-00007 · Cited by 255
Cited by
Sorted by citations
Items 101–121 of 121
Sterling, J. C. (2016) · doi:10.1002/9781118441213.rtd0025 · Cited by 1
Harwood, C. A., & Sterling, J. C. (2024) · doi:10.1002/9781119709268.rook025 · Cited by 1
Neue Standards in der Therapie sexuell übertragbarer Erkrankungen und der HIV-Infektion
Petzoldt, D. (1998) · Springer eBooks · doi:10.1007/978-3-642-71974-5_147
Third trimester antiviral therapy for preventing recurrent genital herpes at delivery
Hollier, L. M., & Wendel, G. D. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004946
Recommended Managements for the Herpes Genitalia
Park, H. J. (2014) · Korean Journal of Urogenital Tract Infection and Inflammation · doi:10.14777/kjutii.2014.9.2.68
Famciclovir for recurrent genital herpes
Varela, A., Arora, A., Mendoza, N., Carrasco, D., & Tyring, S. K. (2007) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.2.5.557
Smith, D. E., & Gold, J. (2007) · Sexual Health · doi:10.1071/sh06060
Johnson, K. E., & Rompalo, A. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50089-5
The Value of Antivirals in Genital Herpes
Woolley, P. D. (1997) · Antiviral chemistry & chemotherapy · doi:10.1177/09563202970080s611
“The ability of famciclovir to suppress the recurrence of genital herpes has also been tested in a multicentre, placebocontrolled, dose-ranging trial in 375 women (Mertz et al., 1997).”
BackgroundJohnston, C., & Wald, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00062-9
Kimberlin, D. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00297-x
Antiviral Therapy for Herpes Simplex Virus Encephalitis
Amalakanti, S., Boppana, S. H., Sivaraj, N., Arepalli, K. V. R., & Suvvari, T. K. (2021) · Journal of Applied Sciences and Clinical Practice · doi:10.4103/jascp.jascp_13_21
Field, H. J., & Whitley, R. J. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0275
Contopoulos‐Ioannidis, D. G., & Wiedermann, B. L. (1999) · Seminars in Pediatric Infectious Diseases · doi:10.1016/s1045-1870(99)80010-7
Update on drugs for herpes zoster and genital herpes
(1998) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1998.361077
Kimberlin, D. W. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50301-1
Cinsel Yolla Bulaşan Hastalıklara Multidisipliner Yaklaşım
Durusu, İ. N., Şen, E. T., Soylu, S., Bozkurt, F., Eren, B., Keleş, İ., Karalar, M., Ulusoy, K., Dur, R., Özdemir, C. Y., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2637
Harrison, G. J. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00255-7
Orolabial and Genital Herpes Clinical Trials: A Meta-analysis of Endpoints
Sloan, A., Mortezavi, M., Gerhart, J. G., Banerjee, A., Alami, N. N., Najera, I., Ahadieh, S., Dalam, A. B., Schiffer, J. T., Patel, R., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf776
Apport des revues systématiques et méta-analyses en réseau en Dermatologie
Cleach, L. L. (2019) · theses.fr (ABES) · doi:10.70675/2be3f9ebzcec0z46a8za809z2bdd2be06c57
2024 guidelines (S3) for the therapeutic management of patients with genital herpes
Joly, E., Lothmann, L., Diallo, K., Fouéré, S., Hantz, S., & Bertolotti, A. (2026) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2026.103507
Metadata
- Authors
- Mertz, G. J.
- Corresponding author
- Mertz, Gregory J.
- ORCID
- Mertz, Gregory J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1997-02-10
- Volume
- 157
- Issue
- 3
- Pages
- 343
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2059870306
- Cited by
- 121
- References
- 29
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 4 · 2021: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 7 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 3
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- famciclovir, genital herpes simplex virus, recurrent herpes, suppressive therapy, oral antiviral therapy, women, time to recurrence, dose comparison, drug safety, drug resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review